Role of Antifungals in decreasing disease severity in ulcerative colitis
Phase 3
Completed
- Conditions
- Health Condition 1: K51- Ulcerative colitis
- Registration Number
- CTRI/2018/11/016292
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 61
Inclusion Criteria
Consecutive diagnosed cases of UC who are willing to participate in the study after signing the consent form
Exclusion Criteria
1.Unable to provide informed consent
2Pregnant/ Lactating mother
3.Renal/Hepatic disorder
4.Serious life threatening co morbidity
5.Patients who are exposed to anti-fungal drugs in last 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method